Evidence map›Paper›PMID 40454095›Full record

ArticleiScience2025

Development of a succinyl CoA:3-ketoacid CoA transferase inhibitor selective for peripheral tissues that improves glycemia in obesity.

Seyed Amirhossein Tabatabaei Dakhili, Kunyan Yang, Hamdah Al Nebaihi, Amanda A Greenwell, Melinda Wuest, Jenilee Woodfield, Rabih Abou Farraj, Christina T Saed, Jordan S F Chan, Rakesh K Bhat and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Seyed Amirhossein Tabatabaei DakhiliFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Kunyan YangFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Hamdah Al NebaihiFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Amanda A GreenwellFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Melinda WuestDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Jenilee WoodfieldDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Rabih Abou FarrajDepartment of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
Christina T SaedFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Jordan S F ChanFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Rakesh K BhatDepartment of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
Indiresh A Mangra-BalaFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Tanin ShafaatiFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Keshav GopalFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Farah EatonFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Sally R FerrariFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Cory S WaggAlberta Diabetes Institute, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Megan E CapozziDuke Molecular Physiology Institute, Duke University, Durham, NC 27701, USA.
Jonathan E CampbellDuke Molecular Physiology Institute, Duke University, Durham, NC 27701, USA.
Michael OverduinDepartment of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
Carlos A Velazquez-MartinezFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
J N Mark GloverDepartment of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
Frank WuestDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Dion R BrocksFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
John R UssherFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
Glucagon and insulin act cooperatively in the regulation of prandial hepatic glycogen metabolismK01DK129417 · NIDDK · UNIVERSITY OF WASHINGTON · PI CAPOZZI, MEGAN · 2021 to 2025
$679k
NIDDK NIH HHS K01 DK129417NIDDK NIH HHS P30 DK017047
6 · The paper itself

Abstract

Many individuals with type 2 diabetes (T2D) cannot take current therapies due to their adverse effects. Thus, new glucose-lowering agents targeting unique mechanisms are needed. Studies have demonstrated that decreasing ketone oxidation, secondary to muscle-specific deletion of succinyl-CoA:3-ketoacid-CoA transferase (SCOT), protects mice against obesity-related hyperglycemia.

Indexed as

Computational molecular modellingDiabetologyMedical biochemistryPharmaceutical compounds formulationPharmacologyPhysiology

Identifiers

PMID40454095
PMCPMC12124683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.